此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Measuring Blood Vessel Density in the Optic Nerve of Multiple Sclerosis Patients With OCTA

2026年6月1日 更新者:Sarah Abdul Fattah Saad、Fayoum University

Quantitative OCT Angiography Differences in Optic Nerve Vascular Density in Multiple Sclerosis: A Case-Control Study

The goal of this observational study is to learn about the effect of multiple sclerosis on the blood flow of the optic nerve of affected patients compared to normal subjects by OCTA. The main question it aims to answer is:

  1. Does MS change the blood flow in the optic nerve?
  2. If it does, can measuring this blood flow be used as a simple sign (a biomarker) to help doctors understand and manage MS?

We used a quick and painless eye scan called Optical Coherence Tomography Angiography (OCTA). This special scan takes detailed pictures of the blood vessels in the optic nerve without needing any injections. We performed this scan on two groups of people: one group with MS and one group without MS, and then compare the results.

In simple terms, why is this important? If we can show that MS affects the optic nerve blood vessels, it could give us a new, quick way to monitor the disease and see how it is progressing, just by doing a simple eye scan.

研究概览

详细说明

The optic nerve is like the main cable that carries visual information from the eye to the brain. In Multiple Sclerosis (MS), the body's immune system mistakenly attacks the protective covering (called myelin) around nerve fibers, including those in the optic nerve. This often causes a condition called optic neuritis, which can lead to vision loss.

While we know MS damages the nerve fibers, we are now trying to understand how it affects the blood vessels that supply oxygen and nutrients to the optic nerve. Are these blood vessels damaged as well? Does reduced blood flow contribute to the nerve damage?

2. The Technology We Are Using

This study uses a advanced, non-invasive imaging technology called Optical Coherence Tomography Angiography (OCTA).

What it does: The OCTA machine uses a safe, dim light beam to scan the optic nerve and macula. It works like a microscopic radar for blood vessels, allowing us to create very detailed, high-resolution 3D maps of the blood flow in the retina and optic nerve without any needles or injections.

What we measure: From these maps, we can quantitatively analyze the vessel density which is a percentage that tells us how much of a specific area is filled with functioning blood vessels. We will focus this measurement on the Radial Peripapillary Capillaries, which are the blood vessels that directly supply the optic nerve head.

3. The Purpose and Potential Impact of This Research

The main goal of this study is to determine if the blood vessel density in the optic nerve is a reliable biological marker (or biomarker) for MS.

A biomarker is an objective, measurable sign of a medical condition. If we can prove that changes in optic nerve blood flow are a consistent marker of MS, it could provide us with:

A new tool to help understand the disease activity in an individual.

A quick and painless way to potentially monitor how the disease is changing over time and whether treatments are effectively protecting the nervous system.

By comparing these detailed OCTA measurements between participants with and without MS, we hope to better understand the role of blood flow in the disease and contribute to improved future care for people living with MS.

研究类型

观察性的

注册 (实际的)

54

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Faiyum Governorate
      • Al Fayyum、Faiyum Governorate、埃及、63514
        • Fayoum University hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

是的

取样方法

非概率样本

研究人群

This case-control study enrolled two groups: group 1; 26 adults with a clinically definite diagnosis of Multiple Sclerosis (Cases) and group 2; 28 age- and sex-matched healthy adults with no history of neurological or significant ocular disease (Controls).

描述

Inclusion Criteria:

  • group 1; patients with multiple sclerosis with optic neuritis.
  • group 2; normal healthy age matched controls

Exclusion Criteria:

  • Other optic nerve diseases as glaucoma, papilledema or conginetal anomalies.
  • Other macular diseases as AMD, CSR, scars …
  • Errors of refraction outside +4 and -6 D range.
  • Media opacity as cataracts or corneal opacities that may interfere with the quality of scans.
  • Signal strength index less than 4\10.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Multiple Sclerosis (MS) Cohort
26 eyes of patients with clinically definite MS
optic nerve head analysis as regards the vessel density and retinal nerve fiber layer thickness and ganglion cell complex analysis as regards thickness and focal loss volume and global loss volume.
Healthy Control Cohort
28 eyes of age- and sex-matched normal subjects
optic nerve head analysis as regards the vessel density and retinal nerve fiber layer thickness and ganglion cell complex analysis as regards thickness and focal loss volume and global loss volume.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
vessel density of the optic nerve head and peripapillary region measured by OCTA
大体时间:Baseline
Difference in microvascular vessel density, as measured by Optical Coherence Tomography Angiography (OCTA), in the optic nerve head and peripapillary region between patients with Multiple Sclerosis and healthy controls. Analysis will include the whole disc area, inside the disc, and individual quadrants.
Baseline

次要结果测量

结果测量
措施说明
大体时间
RNFL thickness
大体时间:Baseline
Retinal Nerve Fiber Layer (RNFL) thickness, measured in micrometers, for the superior and inferior hemispheres of the optic nerve head.
Baseline
GCC thickness
大体时间:Baseline
The thickness of the macular Ganglion Cell Complex (GCC) was measured in micrometers for the superior and inferior hemispheres. These measurements were then analyzed by the device's proprietary software to calculate the Focal Loss Volume (FLV) and Global Loss Volume (GLV) indices.
Baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年1月5日

初级完成 (实际的)

2025年8月3日

研究完成 (实际的)

2025年8月3日

研究注册日期

首次提交

2025年9月26日

首先提交符合 QC 标准的

2026年6月1日

首次发布 (实际的)

2026年6月5日

研究记录更新

最后更新发布 (实际的)

2026年6月5日

上次提交的符合 QC 标准的更新

2026年6月1日

最后验证

2025年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅